GlassScriptPhysician profile
Todd M Kliewer
NPI 1396745741
$2,658.15
in general payments reported to CMS, 2019-2025
35 companies · $568 in 2025
The $568 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.30 · 2020: $11.41 · 2021: $42.90 · 2022: $292 · 2023: $720 · 2024: $943 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898 · Education: $333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.28 |
| Education | $333.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $573.41 | 2019-2025 | |
| Daiichi Sankyo INC. | $220.46 | 2023-2025 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $164.93 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $141.87 | 2023-2025 | Enhertu, Lynparza |
| Novartis Pharmaceuticals Corporation | $138.92 | 2022-2024 | |
| Astellas Pharma US INC | $136.22 | 2019-2024 | Padcev |
| E.R. Squibb & Sons, L.L.C. | $129.36 | 2023-2024 | Opdivo |
| Seagen INC. | $100.68 | 2022-2023 | Padcev, Tukysa, Adcetris |
| Gilead Sciences, INC. | $92.53 | 2022-2025 | Trodelvy |
| Genentech USA, INC. | $88.02 | 2023-2024 | Venclexta, Lunsumio, Columvi |
| Celgene Corporation | $81.74 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Taiho Oncology, INC. | $62.52 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $58.98 | 2023-2024 | Ultomiris |
| Sobi, INC | $58.72 | 2024-2025 | |
| Abbvie INC. | $58.32 | 2024-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $57.10 | 2022-2024 | |
| Myovant Sciences INC. | $51.00 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $48.69 | 2024 | Tazverik, Onivyde |
| Incyte Corporation | $48.12 | 2024-2025 | Monjuvi |
| Stemline Therapeutics INC. | $38.34 | 2025 | Orserdu |
| Array Biopharma INC | $27.73 | 2023 | Mektovi, Xalkori, Lorbrena |
| Karyopharm Therapeutics INC. | $27.62 | 2024 | Xpovio |
| Sun Pharmaceutical Industries INC. | $27.18 | 2025 | |
| Mirati Therapeutics, INC. | $23.38 | 2023 | Krazati |
| Rigel Pharmaceuticals, INC. | $21.51 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Blueprint Medicines Corporation | $21.14 | 2025 | Ayvakit |
| Clovis Oncology, INC. | $20.36 | 2019 | |
| Janssen Biotech, INC. | $19.98 | 2025 | Carvykti |
| Amgen INC. | $19.65 | 2022 | |
| Eisai INC. | $19.04 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $18.81 | 2025 | Libtayo |
| Lilly USA, LLC | $17.38 | 2024 | Jaypirca |
| Tempus Ai, INC | $15.80 | 2025 | Xt Cdx |
| Sumitomo Pharma America, INC. | $14.71 | 2025 | Orgovyx |
| Acrotech Biopharma INC. | $13.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Kliewer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.